Mirae Asset Global Investments’s TG Therapeutics TGTX Stock Holding History

Mirae Asset Global Investments’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-74,538	Closed	-$1.1M	–	2449
2024 Q1	$1.1M	Sell	74,538 -6,643	-8%	-$106K	﹤0.01%	1482
2023 Q4	$1.39M	Sell	81,181 -4,399	-5%	-$51.1K	﹤0.01%	1443
2023 Q3	$715K	Buy	85,580 +17,207	+25%	+$240K	﹤0.01%	1706
2023 Q2	$1.69M	Sell	68,373 -7,957	-10%	-$206K	﹤0.01%	1292
2023 Q1	$1.15M	Buy	76,330 +18,304	+32%	+$278K	﹤0.01%	1470
2022 Q4	$686K	Buy	58,026 +4,099	+8%	+$29.8K	﹤0.01%	1710
2022 Q3	$319K	Buy	53,927 +17,000	+46%	+$112K	﹤0.01%	2133
2022 Q2	$157K	Buy	+36,927	New	+$231K	﹤0.01%	2216

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mirae Asset Global Investments's TGTX Position: Q2 2024 in Review

Mirae Asset Global Investments sold out of TG Therapeutics (TGTX) in Q2 2024, closing a stake of 74,538 shares — an estimated $1.1M sold.

Mirae Asset Global Investments first reported a position in TGTX in Q2 2022 and held it in 8 quarters. The position peaked at $1.69M in Q2 2023. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.

Mirae Asset Global Investments reported no remaining TG Therapeutics position as of Q2 2024 after selling out during the quarter.
Mirae Asset Global Investments sold 74,538 TG Therapeutics shares in Q2 2024, an estimated $1.1M.
Mirae Asset Global Investments first reported a position in TG Therapeutics in Q2 2022 and held it in 8 quarters.
Mirae Asset Global Investments's TG Therapeutics position peaked at $1.69M in Q2 2023.
259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.

Based on Mirae Asset Global Investments's 13F filing for Q2 2024, filed 30 Jul 2024.